Background: With the wide application of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …

Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …

Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …

Background Molecular and genetic alterations of non-small-cell lung cancer (NSCLC) now
play a vital role in patient care of this neoplasm. The authors focused on the impact of …

Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …

Background There are many controversies concerning the best management of epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …

Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …

Objective Brain metastases remain lethal in lung cancer patients. The impacts of epidermal
growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) on the …

Introduction: Traditionally, brain metastases have been treated with stereotactic radiosurgery
(SRS), whole-brain radiation (WBRT), and/or surgical resection. Non-small cell lung cancers …

Aim: To evaluate the real-world impact of brain metastases (BM) among patients with EGFR
mutation-positive (EGFR m) metastatic non-small-cell lung cancer (NSCLC). Materials & …